IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference

On June 1, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York (Press release, IGM Biosciences, JUN 1, 2022, View Source [SID1234615316]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

NeuBase to Participate at the Jefferies Healthcare Conference

On June 1, 2022 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported that company management will present a corporate overview at the Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022 (Press release, NeuBase Therapeutics, JUN 1, 2022, View Source [SID1234615315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Healthcare Conference
Date: Friday, June 10
Time: 9:00am – 9:25am ET
Speaker: Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer and Chairman
A replay of the webcast will be available following the presentation for 90 days. To access the webcast, please click here. Please contact your representative at Jefferies to schedule a one-on-one meeting with NeuBase management during the conference.

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

On June 1, 2022 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that TAZVERIK (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Hainan Pilot Zone"), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma ("ES") and follicular lymphoma ("FL") consistent with the label as approved by the U.S. Food and Drug Administration ("FDA") (Press release, Hutchison China MediTech, JUN 1, 2022, View Source [SID1234615314]). Launched in 2013 and located in China, the Hainan Pilot Zone is a destination for international medical tourism and global hub for scientific innovation, welcoming 83,900 medical tourists in 2020, according to official data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TAZVERIK is a methyltransferase inhibitor of EZH2[1] developed by Epizyme, Inc. ("Epizyme"). It is approved by the FDA for the treatment of certain patients with ES and certain patients with FL under FDA accelerated approval granted in January and June 2020, respectively.

Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "The approval of TAZVERIK in the Hainan Pilot Zone allows patients to gain early access to this first-in-class EZH2 inhibitor in China, as part of our commitment to bringing innovative medicines to people in need. In addition to its use in the Hainan Pilot Zone, we also plan to initiate further registration-enabling studies in China under the terms of our agreement with Epizyme to facilitate wider and easier patient access."

In August 2021, HUTCHMED entered into a strategic collaboration with Epizyme to research, develop, manufacture and commercialize TAZVERIK in China, Hong Kong, Macau and Taiwan.

About FL and ES
Follicular lymphoma (FL) is a subtype of non-Hodgkin’s lymphoma ("NHL"). FL accounts for approximately 17% of NHL. In 2020, there were an estimated 16,000 and 13,000 new cases of FL in China and the U.S., respectively. [2],[3],[4]

Epithelioid sarcoma (ES) is a rare, slow-growing type of soft tissue cancer. Radical tumor resection is the primary treatment for patients with ES. However, ES is known for its high propensity for locoregional recurrence and distant metastases. The survival of patients with ES is often unsatisfactory with very limited treatment options.[5]

About TAZVERIK (tazemetostat)
TAZVERIK is a methyltransferase inhibitor indicated in the United States for the treatment of:

Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies.
Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval by the U.S. FDA based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

View the U.S. Full Prescribing Information here: www.tazverik.com

About Tazemetostat Clinical Development in China
HUTCHMED and Epizyme are developing tazemetostat in various hematological and solid tumors in Greater China, with HUTCHMED leading the China portion of Epizyme’s SYMPHONY-1 study. HUTCHMED and Epizyme also intend to conduct additional global studies jointly.

SYMPHONY-1 (EZH-302) is an international, multicenter, randomized, double-blind, active-controlled, 3-stage, biomarker-enriched, confirmatory Phase 1b/3 study, which is designed to evaluate the safety and efficacy of tazemetostat in combination with R² in patients with relapsed or refractory FL after at least one prior line of therapy(clinicaltrials.gov identifier: NCT04224493).

We intend to initiate a bridging study in FL to support registration of tazemetostat in China, as well as several combination studies of tazemetostat with HUTCHMED assets.

Almac Discovery nominates a first candidate molecule from its Protein Drug Conjugate (PDC) Platform to progress into pre-clinical development

On June 1, 2022 Almac Discovery, a research driven drug discovery company and member of the Almac Group, reported the nomination of a new pre-clinical candidate molecule (ADP-c389), a novel Protein Drug Conjugate (PDC) targeting the tumour-associated antigen ROR1, for the treatment of refractory solid and haematological cancers (Press release, Almac, JUN 1, 2022, View Source [SID1234615313]). This follows an extensive profiling exercise in which ADP-c389 has demonstrated an excellent preclinical efficacy profile in a range of models, a large therapeutic index and robust preclinical development potential.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This nomination represents the first candidate molecule to be generated using Almac Discovery’s novel PDC platform. The platform combines the use of single chain antigen binding domains with Almac’s proprietary linker:payload and conjugation technologies to produce first and best in class compounds that target unmet needs in oncology.

ROR1 is a novel tumour-associated antigen and was selected as the first target for the platform due to its selective expression pattern on different tumour types including triple-negative breast cancer, lung cancer, ovarian and colorectal cancer, and its functional role in tumorigenesis, disease progression and drug resistance. With ADP-c389 in hand, the Almac Discovery team are now also exploring additional clinical applications for the molecule in areas of high unmet need.

Dr Graham Cotton, Head of Protein Therapeutics at Almac Discovery, said: "The nomination of this candidate drug represents a significant value inflection point in in the development of our PDC platform and an important step forward in our search for new treatments for solid tumours. This particular molecule has arisen from our strategic collaboration with Elasmogen Ltd, (Aberdeen UK), with whom we have worked to identify a selective, high affinity single domain binding molecule derived from their shark Variable New Antigen Receptor (VNAR) platform. With this, and other differentiating features included in the design of this compound, we are confident that ADP-c389 has the potential to progress to a Best-in-Class drug against this clinically relevant target."

Dr Alan Lamont, VP Business Development and Licensing added: "We are now seeking to identify a partner to facilitate clinical development of this asset and take this molecule through the next stages of development."

Taiho Pharmaceutical to Donate a Total of 4.17 Million Yen to Three Projects Addressing Issues in the Field of Oncology "The First Taiho Smile Support"

On June 1, 2022 Taiho Pharmaceutical Co., Ltd. reported that it will donate a total of 4.17 million yen in matching gift to three projects for the first Taiho Smile Support, a program to support organizations and individuals working to solve social issues in the field of oncology (Press release, Taiho, JUN 1, 2022, View Source [SID1234615312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Taiho Pharmaceutical planned the first Taiho Smile Support to contribute to Goal 3 of the SDGs: "Ensure healthy lives and promote well-being for all at all ages." It then called for projects to address various issues surrounding cancer. Three projects were selected from among the many applications, and all three applicants succeeded in crowdfunding their goal amounts. Taiho Pharmaceutical’s donation, totaling 4.17 million yen, represents 50% of the total funds needed to implement the three projects. Each project will be gradually implemented.

Yokohama Children’s Hospice
UMI TO SORA NO OUCHI (a home of sea and sky): "Connecting Through Green" Project

Through this program, Taiho Pharmaceutical aims to support the dreams of organizations and individuals who are working to address challenges in the field of oncology. In partnership with these organizations, individuals, and all of the people who support them via crowdfunding, Taiho Pharmaceutical seeks to create a world where the precious moments of everyday life keep flowing for people with cancer and their families.

First Taiho Smile Support (Available only in Japanese)
Taiho Smile Support is an initiative to support organizations and individuals seeking to solve various social issues in the field of oncology that cannot be solved by drugs alone. Taiho Pharmaceutical called for organizations and individuals who plan to use crowdfunding to raise funds to address these social issues. The selected organizations and individuals each conducted a crowdfunding campaign and reached their funding target.* They will each receive from Taiho Pharmaceutical, in the form of a donation, matching funds equal to the target they have raised.

* The crowdfunding target (not including the crowdfunding fee) is to be 50% of all funds needed to carry out the project. If the target is met, Taiho Pharmaceutical will provide the remaining 50%. Thus, the success of the crowdfunding campaign will determine whether or not Taiho Pharmaceutical will provide support.